Vista Pharmaceuticals Ltd
Incorporated in 1992, Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulations
- Market Cap ₹ 44.8 Cr.
- Current Price ₹ 7.28
- High / Low ₹ 13.1 / 6.57
- Stock P/E
- Book Value ₹ 7.25
- Dividend Yield 0.00 %
- ROCE -8.53 %
- ROE -10.8 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 1.00 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -12.4% over last 3 years.
- Company has high debtors of 505 days.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.30 | 13.75 | 15.38 | 24.18 | 28.92 | 31.07 | 22.76 | 1.27 | 0.39 | 1.00 | 10.12 | 9.79 | 8.77 | |
| 7.08 | 11.05 | 12.78 | 21.12 | 23.59 | 29.84 | 27.56 | 3.00 | 1.66 | 5.32 | 13.41 | 13.81 | 15.74 | |
| Operating Profit | 1.22 | 2.70 | 2.60 | 3.06 | 5.33 | 1.23 | -4.80 | -1.73 | -1.27 | -4.32 | -3.29 | -4.02 | -6.97 |
| OPM % | 14.70% | 19.64% | 16.91% | 12.66% | 18.43% | 3.96% | -21.09% | -136.22% | -325.64% | -432.00% | -32.51% | -41.06% | -79.48% |
| 0.03 | 0.01 | 0.02 | 0.06 | 0.40 | 2.95 | 3.75 | 0.20 | 0.17 | 0.40 | 0.07 | 0.44 | 0.55 | |
| Interest | 0.00 | 0.41 | 0.77 | 0.88 | 1.57 | 1.67 | 1.54 | 1.55 | 0.90 | 1.34 | 1.24 | 0.97 | 0.80 |
| Depreciation | 0.77 | 1.05 | 1.02 | 1.02 | 1.34 | 1.36 | 1.35 | 0.73 | 0.62 | 0.62 | 0.72 | 0.74 | 0.75 |
| Profit before tax | 0.48 | 1.25 | 0.83 | 1.22 | 2.82 | 1.15 | -3.94 | -3.81 | -2.62 | -5.88 | -5.18 | -5.29 | -7.97 |
| Tax % | 2.08% | -8.80% | 8.43% | -1.64% | 22.70% | 18.26% | -6.60% | -47.24% | -66.03% | -3.57% | -12.93% | -12.10% | |
| 0.47 | 1.36 | 0.77 | 1.25 | 2.19 | 0.94 | -3.68 | -2.01 | -0.89 | -5.66 | -4.51 | -4.65 | -6.70 | |
| EPS in Rs | 0.06 | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -16% |
| 3 Years: | 193% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | % |
| TTM: | -99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -10% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -10% |
| 3 Years: | -12% |
| Last Year: | -11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.00 | 5.00 | 5.00 | 5.31 | 5.83 | 6.07 | 6.07 | 7.36 | 7.36 | 7.51 | 9.43 | 12.31 | 12.31 |
| Reserves | -5.91 | 5.44 | 6.21 | 11.29 | 26.03 | 29.73 | 23.57 | 25.49 | 28.09 | 29.20 | 31.03 | 33.11 | 32.33 |
| 0.00 | 4.04 | 7.88 | 11.33 | 11.06 | 11.17 | 15.47 | 10.71 | 12.55 | 9.96 | 7.96 | 7.40 | 8.50 | |
| 4.97 | 8.30 | 7.29 | 13.69 | 10.08 | 5.79 | 6.01 | 9.05 | 7.59 | 9.36 | 9.56 | 7.47 | 7.82 | |
| Total Liabilities | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 60.29 | 60.96 |
| 11.69 | 10.73 | 9.96 | 13.46 | 17.67 | 20.52 | 20.66 | 19.93 | 19.33 | 19.74 | 19.32 | 18.70 | 18.64 | |
| CWIP | 0.00 | 0.00 | 0.00 | 1.99 | 7.11 | 8.54 | 8.78 | 9.08 | 9.08 | 9.33 | 9.82 | 10.14 | 10.55 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 | 0.05 | 0.07 |
| 2.37 | 12.05 | 16.42 | 26.17 | 28.20 | 23.67 | 21.66 | 23.56 | 27.15 | 26.94 | 28.82 | 31.40 | 31.70 | |
| Total Assets | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 60.29 | 60.96 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -3.53 | -2.50 | 2.57 | -4.58 | 3.30 | 0.80 | -6.75 | -0.99 | -1.71 | -4.91 | -6.98 | |
| 0.01 | -0.09 | -0.24 | -3.61 | -10.61 | -5.65 | -1.73 | -0.30 | -0.01 | -1.27 | -0.79 | -0.44 | |
| 0.00 | 3.63 | 3.07 | 6.36 | 11.22 | 1.43 | 0.28 | 6.96 | 0.94 | 3.11 | 5.59 | 8.06 | |
| Net Cash Flow | -0.08 | 0.00 | 0.34 | 5.32 | -3.98 | -0.92 | -0.64 | -0.09 | -0.07 | 0.13 | -0.11 | 0.64 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45.30 | 299.70 | 231.15 | 136.01 | 137.06 | 98.09 | 164.86 | 623.66 | 9,789.49 | 4,106.25 | 515.04 | 504.81 |
| Inventory Days | 51.61 | 10.20 | 96.66 | 184.54 | 249.51 | 161.60 | 147.59 | 4,840.00 | 9,203.92 | 990.53 | 278.78 | 359.32 |
| Days Payable | 323.11 | 359.43 | 236.24 | 293.13 | 208.80 | 75.56 | 78.67 | 2,555.00 | 5,297.43 | 1,007.30 | 304.24 | 244.35 |
| Cash Conversion Cycle | -226.21 | -49.53 | 91.57 | 27.41 | 177.77 | 184.14 | 233.77 | 2,908.66 | 13,695.97 | 4,089.48 | 489.58 | 619.78 |
| Working Capital Days | -110.38 | -8.49 | 205.76 | 12.23 | 136.94 | 136.51 | 80.83 | 1,681.30 | 10,154.49 | 3,460.20 | 317.75 | 440.31 |
| ROCE % | 5.42% | 14.09% | 9.53% | 8.93% | 12.39% | 6.27% | -5.21% | -5.10% | -3.76% | -9.59% | -7.74% | -8.53% |
Documents
Announcements
-
Update on board meeting
5 Feb - Board meeting on 13 Feb 2026 to consider unaudited results and limited review for quarter/nine months ended 31.12.2025.
-
Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025.
2. Limited Review Report Quarter And Nine Months 31.12.2025.
3. Any Other Business With The Permission Of The Chair.
5 Feb - Board meeting on 13-Feb-2026 to approve Q3/9M unaudited results and limited review for 31-12-2025.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - 'Joint Venture Partnership Between Pleiades Therapeutics And Vista Pharmaceuticals Ltd'
3 Feb - Vista Pharmaceuticals and Pleiades Therapeutics form JV to develop generic and specialty drugs for US and ROW markets.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jan - Compliance - Certificate under Reg 74(5) of SEBI (DP) Regulations
-
Closure of Trading Window
30 Dec 2025 - Trading window closed from 1 Jan 2026 until 48 hours after unaudited Q4 (31.12.2025) results declaration.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers, produce markets, and distributes pharmaceutical products. The company has its USFDA Approved Manufacturing Facility in India and its Marketing and Distribution Center in the USA.